These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 15368577)
1. Binding mode of TMC-95A analogues to eukaryotic 20S proteasome. Kaiser M; Groll M; Siciliano C; Assfalg-Machleidt I; Weyher E; Kohno J; Milbradt AG; Renner C; Huber R; Moroder L Chembiochem; 2004 Sep; 5(9):1256-66. PubMed ID: 15368577 [TBL] [Abstract][Full Text] [Related]
2. TMC-95-based inhibitor design provides evidence for the catalytic versatility of the proteasome. Groll M; Götz M; Kaiser M; Weyher E; Moroder L Chem Biol; 2006 Jun; 13(6):607-14. PubMed ID: 16793518 [TBL] [Abstract][Full Text] [Related]
3. TMC-95A analogues with endocyclic biphenyl ether group as proteasome inhibitors. Kaiser M; Milbradt AG; Siciliano C; Assfalg-Machleidt I; Machleidt W; Groll M; Renner C; Moroder L Chem Biodivers; 2004 Jan; 1(1):161-73. PubMed ID: 17191784 [TBL] [Abstract][Full Text] [Related]
4. 20S proteasome inhibition: designing noncovalent linear peptide mimics of the natural product TMC-95A. Groll M; Gallastegui N; Maréchal X; Le Ravalec V; Basse N; Richy N; Genin E; Huber R; Moroder L; Vidal J; Reboud-Ravaux M ChemMedChem; 2010 Oct; 5(10):1701-5. PubMed ID: 20715286 [No Abstract] [Full Text] [Related]
5. Dimerized linear mimics of a natural cyclopeptide (TMC-95A) are potent noncovalent inhibitors of the eukaryotic 20S proteasome. Desvergne A; Genin E; Maréchal X; Gallastegui N; Dufau L; Richy N; Groll M; Vidal J; Reboud-Ravaux M J Med Chem; 2013 Apr; 56(8):3367-78. PubMed ID: 23540790 [TBL] [Abstract][Full Text] [Related]
6. Linear TMC-95-based proteasome inhibitors. Basse N; Piguel S; Papapostolou D; Ferrier-Berthelot A; Richy N; Pagano M; Sarthou P; Sobczak-Thépot J; Reboud-Ravaux M; Vidal J J Med Chem; 2007 Jun; 50(12):2842-50. PubMed ID: 17511440 [TBL] [Abstract][Full Text] [Related]
7. Bifunctional inhibitors of the trypsin-like activity of eukaryotic proteasomes. Loidl G; Groll M; Musiol HJ; Ditzel L; Huber R; Moroder L Chem Biol; 1999 Apr; 6(4):197-204. PubMed ID: 10099130 [TBL] [Abstract][Full Text] [Related]
8. TROSY-based NMR evidence for a novel class of 20S proteasome inhibitors. Sprangers R; Li X; Mao X; Rubinstein JL; Schimmer AD; Kay LE Biochemistry; 2008 Jul; 47(26):6727-34. PubMed ID: 18540636 [TBL] [Abstract][Full Text] [Related]
9. Crystal structure of the 20 S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor. Groll M; Koguchi Y; Huber R; Kohno J J Mol Biol; 2001 Aug; 311(3):543-8. PubMed ID: 11493007 [TBL] [Abstract][Full Text] [Related]
10. Quantitative dynamics and binding studies of the 20S proteasome by NMR. Sprangers R; Kay LE Nature; 2007 Feb; 445(7128):618-22. PubMed ID: 17237764 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes. Andrews MJ; McInnes C; Kontopidis G; Innes L; Cowan A; Plater A; Fischer PM Org Biomol Chem; 2004 Oct; 2(19):2735-41. PubMed ID: 15455144 [TBL] [Abstract][Full Text] [Related]
12. Snapshots of the fluorosalinosporamide/20S complex offer mechanistic insights for fine tuning proteasome inhibition. Groll M; McArthur KA; Macherla VR; Manam RR; Potts BC J Med Chem; 2009 Sep; 52(17):5420-8. PubMed ID: 19678642 [TBL] [Abstract][Full Text] [Related]
13. Elucidation of the structure and intermolecular interactions of a reversible cyclic-peptide inhibitor of the proteasome by NMR spectroscopy and molecular modeling. Stauch B; Simon B; Basile T; Schneider G; Malek NP; Kalesse M; Carlomagno T Angew Chem Int Ed Engl; 2010 May; 49(23):3934-8. PubMed ID: 20408152 [No Abstract] [Full Text] [Related]
14. Novel beta-lactam derivatives: potent and selective inhibitors of the chymotrypsin-like activity of the human 20S proteasome. Imbach P; Lang M; García-Echeverría C; Guagnano V; Noorani M; Roesel J; Bitsch F; Rihs G; Furet P Bioorg Med Chem Lett; 2007 Jan; 17(2):358-62. PubMed ID: 17095212 [TBL] [Abstract][Full Text] [Related]
15. Complex of an active mu-opioid receptor with a cyclic peptide agonist modeled from experimental constraints. Fowler CB; Pogozheva ID; Lomize AL; LeVine H; Mosberg HI Biochemistry; 2004 Dec; 43(50):15796-810. PubMed ID: 15595835 [TBL] [Abstract][Full Text] [Related]
16. Noncovalent inhibition of 20S proteasome by pegylated dimerized inhibitors. Maréchal X; Pujol A; Richy N; Genin E; Basse N; Reboud-Ravaux M; Vidal J Eur J Med Chem; 2012 Jun; 52():322-7. PubMed ID: 22440858 [TBL] [Abstract][Full Text] [Related]
17. Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. Mallik B; Katragadda M; Spruce LA; Carafides C; Tsokos CG; Morikis D; Lambris JD J Med Chem; 2005 Jan; 48(1):274-86. PubMed ID: 15634022 [TBL] [Abstract][Full Text] [Related]
18. 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Borissenko L; Groll M Chem Rev; 2007 Mar; 107(3):687-717. PubMed ID: 17316053 [No Abstract] [Full Text] [Related]
20. Structure-based design of derivatives of tyropeptin A as the potent and selective inhibitors of mammalian 20S proteasome. Momose I; Umezawa Y; Hirosawa S; Iinuma H; Ikeda D Bioorg Med Chem Lett; 2005 Apr; 15(7):1867-71. PubMed ID: 15780623 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]